February 15, 2019
Recent clinical misses (CLBS and SLDB), volatility, low volume and sentiment qualms add to the risk of share pricing also, the IBB has also been up five (5) up sessions in a row without indicating in the pre-open …
Follow the bouncing share pricing
Pre-open indications: 1 BUY, 1 SELL and 3 TRADEs
You can lead a horse to water but you can't make him drink' is a proverb which means that you can give investors an opportunity but can’t force them to take it.
February 11, 2019
Q4/18 financial results is a scorecard of (AKA) earnings of 45 covered companies
3 out of 45 ...The current LPS (loss per share) or net income, cash positions i.e. "runways" and correlation of "street" expectations - it's a reflection of this universe's investing "status"
Investors can gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
February 15, 2019
Making-up for lost ground as the sector shakes off clinical miss risks
Fundamentals are mutable as investor confidence has been ravaged by the sudden rotations of share pricing values
Pre-open indications: 4 HITs and 1 MISS
It’s not hard to be right so often; that’s why the term “quantamental,” a blend of the two styles, may soon become common parlance among investors and traders.
February 11, 2019
Q4/18 financial results is a scorecard of (AKA) earnings of 45 covered companies 3 out of 45 ... The current LPS (loss per share) or net income, cash positions i.e. "runways" and correlation of "street" expectations - it's a reflection of this universe's investing "status" Investors can gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
January 23, 2019
The opening was about the “feeling” of the oversold but, the reliance of trust versus conviction pushes the session … The Advance/Decline Line has deteriorated ... Yet the “bottoms” are being bought! There’s a difference between trust and conviction. Trust is something you can rely on, beyond certainty. Conviction doesn't demand that you, or anyone else, play by the rules. After gains, there’s pain; followed by advances, declines and other progressions or was it regressions? Confidence perceived is not always value achieved!
January 22, 2019
EDIT (-$4.48 or -17.13%), Intellia Therapeutics (NTLA -$1.05 or -6.88%) and CRISPR Therapeutics (CRSP -$4.07 or -10.96%) equities plunged EDIT volume is HIGH with 3.7 M shares traded <3 month average = 792.8 K shares, CRSP volume is also HIGH with 1.79 M shares traded <3 month average = 834.7 K shares> and NTLA volume is as LOWER with 577.05 K shares traded <3 month average = 694.3 K shares>
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
February 15, 2019
RegMed Investors’ (RMi) closing bell: a rebound of the oversold
February 15, 2019
RegMed Investors’ (RMi) pre-open: the known and the unknowns
February 14, 2019
RegMed Investors’ (RMi) closing bell: buzz kill
February 14, 2019
RegMed Investors’ (RMi) pre-open: another missed data event as a hammer falls
February 13, 2019
RegMed Investors’ (RMi) closing bell: resistance
February 13, 2019
RegMed Investors’ (RMi) pre-open: market actions compel focus to be on short-termism
February 12, 2019
RegMed Investors’ (RMi) closing bell: tailwinds keep the sector up
February 12, 2019
RegMed Investors’ (RMi) pre-open: science will eventually win the battle of disease
February 11, 2019
RegMed Investors’ (RMi) closing bell: investing in the sector is an opportunity and a risk
February 11, 2019
Regenerative Medicine Earnings Scorecard - Q4/18 - to date
February 11, 2019
RegMed Investors’ (RMi) pre-open: what’s new, sector anticipates Q4 and FY18 results, per share pricing losses, cash positions and “runways”
© 2019 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
